



REVIEW ARTICLE

EXPLORING BIOACTIVE CONSTITUENTS: A REVIEW ON THE PHYTOCHEMICAL DIVERSITY OF LEAVES WITH ANTI-DIABETIC ACTIVITY

Rishabh Gupta^{*}, G Pavan Kumar, Gyan Singh, Jitendra Malik, Surendra Pratap Singh, Sunil Kumar

Faculty of Pharmacy, P.K. University, Thanra - 473665, Shivpuri, Madhya Pradesh, India.

Article History

Received: 13 November 2023

Revised: 18 December 2023

Accepted: 01 January 2024

Published: 25 March 2024

Correspondence should be addressed to

Rishabh Gupta,
Research Scholar, Faculty of
Pharmacy, PK University, Thanra -
473665, Madhya Pradesh, India.

Email- rishabhguptasdp@gmail.com

ABSTRACT: This paper investigates in detail the variety of phytochemicals found in different leaves that have been shown to have anti-diabetic properties. The ongoing worldwide health crisis of diabetes mellitus has prompted researchers to look for efficient treatment solutions, especially those derived from natural sources. Many plant species' leaves have been studied for their bioactive components that may influence how glucose is metabolised and lessen the symptoms of diabetes. The phytochemicals found in these leaves, including as flavonoids, alkaloids, terpenoids, and phenolic compounds, are the subject of contemporary study, which is summarised in this article. Furthermore, the processes that underlie their anti-diabetic activities are clarified, providing insight into their potential as therapeutic agents in the future. Our goal is to contribute to the development of new diabetes therapies by offering insightful information on the wide range of bioactive components present in leaves that have anti-diabetic qualities.

Key Words: Phytochemicals, Leaves, Anti-Diabetic Activity, Diabetes Mellitus, Bioactive Constituents, Flavonoids, Alkaloids, Terpenoids, Phenolic Compounds.

I. INTRODUCTION

Diabetes mellitus is a serious worldwide health issue that is defined by high blood glucose levels brought on by deficiencies in either insulin activity or secretion [1]. The World Health Organization (WHO) estimates that 422 million people globally had diabetes in 2014, and by 2040, that number is expected to climb to 642 million. The increasing frequency of this chronic illness highlights the pressing need for efficient treatment measures to lessen its impact [2].

Natural sources have attracted a lot of interest in the search for innovative anti-diabetic medications. Traditional medical systems have long acknowledged the potential of botanicals in the treatment of diabetes since they are based on the use of treatments derived from plants [3]. Natural products exhibit a complex tapestry of bioactive molecules with prospective therapeutic effects, drawing from a huge pool of chemical variety. Making use of nature's rich pharmacopoeia, scientists have worked to find and describe plant components that might alter glucose metabolism and reduce the symptoms of diabetes [4].

Leafy greens stand out as especially interesting natural sources of bioactive substances that may have anti-diabetic effects. Plants' leaves are active metabolic centres that actively synthesise and accumulate a variety of phytochemicals to carry out a range of ecological functions [5]. A growing body of research indicates that certain leaves have an abundance of bioactive components with anti-diabetic properties. The phytochemical repertory of leaves includes terpenoids, phenolic

chemicals, alkaloids, and flavonoids, providing a diverse armament for fighting diabetes [6].

The scientific potential of leaf bioactive elements as sources of new therapeutic agents, as well as their historical usage in traditional medicine systems, provide justification for investigating their anti-diabetic action. Through investigating the variety of phytochemicals found in leaves and clarifying their modes of action, scientists hope to find encouraging leads for the creation of novel anti-diabetic medications [7].

We give a thorough investigation of the bioactive components found in different leaves that have been shown to have anti-diabetic properties in this review. To shed light on the wide range of phytochemicals present in leaves and their possible use in the treatment of diabetes, we have conducted an integrated study of previous research results. Through the synthesis of current information and the identification of knowledge gaps, we want to further the continuous search for efficient diabetic therapies.






II. PHYTOCHEMICAL DIVERSITY IN LEAVES WITH ANTI-DIABETIC ACTIVITY

A. Flavonoids

Plants include a broad family of polyphenolic molecules called flavonoids, which have a variety of biological functions, including the ability to prevent diabetes. Numerous flavonoid kinds have been found in leaves, each with unique structural traits and pharmacological qualities [8].

- Types of Flavonoids Found in Leaves:** A variety of subclasses of flavonoids, including as flavones, flavonols, flavanones, and anthocyanins, are present in leaves. The phenylpropanoid route is used in the biosynthesis of these chemicals, producing a wide range of structures with different levels of hydroxylation and glycosylation [9].
- Mechanisms of Action in Diabetes Management:** There are many ways in which flavonoids' anti-diabetic effects are mediated, such as:
 - Insulin Sensitization:** By influencing insulin signalling pathways including the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and encouraging glucose absorption in peripheral tissues, flavonoids increase insulin sensitivity.
 - Pancreatic β -Cell Protection:** By reducing oxidative stress and inflammation, certain flavonoids have cytoprotective effects on pancreatic β -cells, maintaining their viability and function.
 - Inhibition of Gluconeogenesis:** By blocking important hepatic gluconeogenic enzymes, flavonoids lower the amount of glucose produced naturally.
 - Antioxidant Activity:** Strong antioxidant qualities found in flavonoids prevent oxidative stress from damaging pancreatic β -cells and other peripheral tissues linked to the aetiology of diabetes [10].

Table 1: Summarizing Flavonoids and Their Anti-Diabetic Properties

Flavonoid	Plant Source	Chemical Structure	Mechanism of Action	Anti-Diabetic Effects
Quercetin	Onion, kale, apples		Insulin sensitization: Activation of PI3K/Akt pathway, Glucose uptake	Improved insulin sensitivity, Enhanced glucose uptake [11]
Kaempferol	Spinach, broccoli, tea		Inhibition of hepatic gluconeogenesis, Antioxidant activity	Reduced hepatic glucose output, Protection against oxidative stress [12]
Rutin	Buckwheat, citrus fruits		Insulin sensitization, Anti-inflammatory effects	Enhanced insulin sensitivity, Modulation of inflammatory pathways [13]
Myricetin	Berries, nuts, grapes		Activation of AMPK pathway, Inhibition of α -glucosidase	Improved glucose uptake, Reduction in postprandial blood glucose levels [14]
Luteolin	Celery, parsley, thyme		Inhibition of NF- κ B signaling, Regulation of GLUT4 translocation	Anti-inflammatory effects, Enhanced glucose uptake [15]

B. Alkaloids

Alkaloids are nitrogen-containing substances that are present in a wide range of plants. They have a variety of pharmacological properties, some of which may have an anti-diabetic impact. A diverse range of alkaloids, each with distinct chemical structures and biological characteristics, are stored in leaves [16].

- Identification of Alkaloids in Leaves:** The alkaloids found in leaves are diverse in terms of their chemical makeup; they include isoquinoline alkaloids, quinoline alkaloids, and indole alkaloids. These substances are usually found via solvent extraction, chromatography, and spectroscopic examination as part of phytochemical screening techniques [17].

2. Anti-diabetic Effects and Potential Mechanisms:





Leaf-derived alkaloids have shown encouraging anti-diabetic benefits via a variety of methods, such as:

- **Pancreatic β -Cell Protection:** By reducing oxidative stress and inflammation, some alkaloids have cytoprotective effects on pancreatic β -cells, maintaining their viability and function [18].
- **Glucose-Lowering Activity:** By increasing insulin release from pancreatic β -cells or boosting

insulin sensitivity in target tissues, alkaloids have the potential to influence glucose metabolism [19].

- **Inhibition of Gluconeogenesis:** Certain alkaloids have the ability to block important hepatic gluconeogenic enzymes, which lowers the amount of glucose produced naturally [20].
- **Regulation of Lipid Metabolism:** Alkaloids may affect how fat is metabolised, which might lead to better glycemic control and a reduction in the problems associated with diabetes [21].

Table 2: Presenting alkaloids and their anti-diabetic activities

Alkaloid	Plant Source	Chemical Structure	Mechanism of Action	Anti-Diabetic Effects
Berberine	<i>Berberis species</i>		Activation of AMPK pathway, Inhibition of PTP1B	Improved insulin sensitivity, Glucose-lowering effects [22]
Vincamine	<i>Vinca minor</i>		Enhancement of insulin secretion, Regulation of glucose metabolism	Increased insulin secretion, Improved glucose tolerance [23]
Camptothecin	<i>Camptotheca acuminata</i>		Inhibition of α -glucosidase, Antioxidant activity	Reduction in postprandial blood glucose levels, Protection against oxidative stress [24]
Reserpine	<i>Rauvolfia serpentina</i>		Regulation of sympathetic nervous system, Modulation of insulin secretion	Improved insulin sensitivity, Glucose-lowering effects [25]





C. Terpenoids

Leaf extracts are rich in terpenoids, a broad family of natural chemicals formed from isoprene units that may have anti-diabetic effects. Terpenoids are bioactive substances.

1. **Diversity of Terpenoids in Leaf Extracts:** Numerous terpenoids, including mono-, sesqui-, di-, and triterpenoids, are present in leaf extracts; these compounds differ in their molecular makeup and biological properties. The mevalonate or methylerythritol phosphate routes are used to biosynthesize these terpenoids, which result in a wide range of structurally varied molecules with possible medicinal applications [26].
2. **Roles in Glucose Metabolism Regulation:** Through a variety of processes, terpenoids included in leaf extracts regulate the metabolism of glucose. These pathways include:

- **Insulin Sensitization:** By modifying insulin signalling pathways, such as the PI3K/Akt pathway, several terpenoids increase insulin sensitivity and improve peripheral tissues' absorption and use of glucose [27].
- **Inhibition of Gluconeogenesis:** Some terpenoids reduce endogenous glucose synthesis and aid in glycemic management by inhibiting important enzymes involved in hepatic gluconeogenesis [28].
- **Stimulation of Insulin Secretion:** Some terpenoids may increase pancreatic β -cells' production of insulin, which would help to maintain euglycemia and promote glucose clearance [29].

Table 3: The chemical structures of key terpenoids with anti-diabetic activity [30]





Terpenoid	Chemical Structure
α -Pinene	
β -Caryophyllene	
Limonene	
β -Sitosterol	

D. Phenolic Compounds

Phenolic chemicals are a broad class of secondary metabolites found in large quantities in leaves. They are important for many biological functions and have great promise for the treatment of diabetes.

- Presence of Phenolic Compounds in Leaves:** Leafy greens are abundant in phenolic compounds, which include flavonoids, phenolic acids, lignans, and stilbenes, among many more subclasses. These substances, which are produced by the phenylpropanoid and shikimate pathways, give leaves their colour, taste, and antioxidant characteristics [31].
- Impact on Insulin Sensitivity and Glucose Uptake:** The main ways that phenolic chemicals improve glucose uptake and insulin sensitivity are through:
 - Insulin Sensitization:** By modifying insulin signalling pathways, such as the PI3K/Akt pathway, several phenolic substances increase insulin sensitivity and improve peripheral tissues' absorption and use of glucose [32].
 - Glucose Uptake Enhancement:** Phenolic chemicals increase cellular glucose absorption and utilisation by encouraging the translocation of glucose transporter type 4 (GLUT4) to the plasma membrane [33].

Table 4: Molecular structures of representative phenolic compounds and their activities in diabetes management [34-37]

Phenolic Compound	Structure	Activity in Diabetes Management
Resveratrol		Insulin sensitization, Glucose uptake enhancement, Anti-inflammatory effects
Quercetin		Insulin sensitization, Enhanced glucose uptake, Anti-inflammatory effects
Epigallocatechin Gallate (EGCG)		Insulin sensitization, Glucose uptake enhancement, Antioxidant activity
Curcumin		Insulin sensitization, Anti-inflammatory effects, Antioxidant activity

III. MECHANISMS UNDERLYING ANTI-DIABETIC EFFECTS

A. Insulin Sensitizing Effects Insulin sensitising effects pertain to the capacity of certain substances to augment target tissues' reaction to insulin, thereby enhancing glucose uptake and utilisation [38]. Mechanisms involved in insulin sensitization include:

- Enhanced translocation of glucose transporter type 4 (GLUT4) to the cell membrane as a result of activation of insulin signalling pathways, such as the phosphatidylinositol-3-kinase (PI3K)/Akt pathway [39].
- Increased insulin sensitivity and glucose absorption are the results of altering intracellular signalling cascades involved in insulin action, such as the AMP-activated protein kinase (AMPK) pathway [40].
- Control of fat tissue metabolism and adipokine production, affecting glucose homeostasis and systemic insulin sensitivity [41].

B. Inhibition of Glucose Absorption Blocking the enzymes or transporters that help food glucose enter the circulation from the intestinal lumen is known as inhibiting glucose absorption [42]. Mechanisms of action include:

- inhibition of the enzymes α -glucosidase and α -amylase, which break down complex carbs into easily absorbed monosaccharides and lower blood glucose levels after a meal.
- inhibition of the intestinal epithelium's sodium-glucose co-transporters (SGLTs), which stops glucose from being reabsorbed into enterocytes and then entering the bloodstream [43].

C. Regulation of Gluconeogenesis The process of de novo glucose production, known as gluconeogenesis, which largely occurs in the liver, is essential for regulating blood glucose levels during fasting [44]. Regulation of gluconeogenesis involves:

- reduction in the amount of glucose produced by the liver as a result of inhibition of important gluconeogenic pathway enzymes, such as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK).
- Reduced expression of gluconeogenic enzymes is the consequence of transcriptional regulators that are involved in controlling the expression of gluconeogenic genes, such as forkhead box O1 (FoxO1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α) [45].

D. Enhancement of Insulin Secretion Potentiation of pancreatic β -cell activity and insulin release in response to glucose stimulation are necessary for the enhancement of insulin production [46]. Mechanisms underlying this effect include:

- insulin exocytosis is caused by the opening and closing of ATP-sensitive potassium (KATP) channels, which results in membrane depolarization and the subsequent influx of calcium ions.
- Increased insulin secretion is the outcome of altering the cAMP-mediated and intracellular calcium signalling pathways that are involved in the exocytosis of insulin granules.
- Insulin production and secretion are encouraged, pancreatic β -cells are protected from oxidative stress and inflammation, and their functional integrity and viability are maintained [47].

IV. POTENTIAL THERAPEUTIC APPLICATIONS

A. Development of Leaf-Derived Extracts or Compounds as Anti-Diabetic Agents

Leaf-derived extracts and compounds are rich sources of bioactive chemicals with a variety of pharmacological activities, making them very promising as possible anti-diabetic medicines [48]. Several crucial factors must be taken into account in the development of leaf-derived medicines for the control of diabetes:

- **Identification of Bioactive Compounds:** Leaf extracts include bioactive ingredients that must be identified and characterised by thorough phytochemical investigation. This include determining each compound's structure, isolating it, and evaluating its pharmacological effects [49].

- **Evaluation of Efficacy and Safety:** Preclinical research is done to assess the anti-diabetic activity, mechanisms of action, and safety profiles of chemicals or extracts produced from leaves. This research includes in vitro experiments and animal models. These findings guide future clinical research and provide insightful information about their possible therapeutic value [50].
- **Clinical Trials:** Clinical studies are carried out on humans with diabetes to evaluate the safety, tolerability, and effectiveness of treatments derived from leaves. Thorough investigation of outcomes including insulin sensitivity, glycemic control, and indicators of problems associated to diabetes is part of these studies, which provide vital data for clinical practise and regulatory approval [51].

B. Challenges and Opportunities in Translating Preclinical Findings to Clinical Use

There are a number of potential and problems in converting preclinical research on leaf-derived medicines to clinical use:

- **Standardization and Quality Control:** Clinical development requires that leaf-derived extracts or chemicals be consistent and repeatable. Essential factors to take into account include standardising extraction techniques, formulations, and dosage forms as well as implementing quality control procedures to evaluate stability and purity [52].
- **Bioavailability and Pharmacokinetics:** To guarantee sufficient systemic exposure and therapeutic effectiveness, leaf-derived chemical bioavailability and pharmacokinetic characteristics must be optimised. Techniques include dosage modification, formulation improvement, and innovative drug delivery methods may improve tissue distribution and bioavailability [53].
- **Safety and Toxicity:** For clinical translation, evaluating the safety profile and possible toxicity of treatments derived from leaves is crucial. Thorough preclinical investigations are carried out to analyse possible side effects and determine safe dose regimes. These investigations include toxicity testing and safety pharmacology evaluations [54].
- **Regulatory Approval and Market Access:** Obtaining regulatory agency approval and navigating regulatory procedures for therapies generated from leaves need a significant time, resource, and knowledge commitment. Submissions to regulatory bodies need to show that the product is safe, effective, and of high quality while meeting strict requirements and rules [55].

CONCLUSION

In summary, the investigation of the phytochemical variety in leaves has uncovered a wide range of bioactive substances that hold great promise for the treatment of diabetes. We have discovered many kinds of phytochemicals that are found in leaves and have anti-diabetic properties, such as flavonoids, alkaloids, terpenoids, and phenolic compounds. These have been discovered via extensive study efforts. These substances improve glycemic control and metabolic balance by acting via a variety of mechanisms, including insulin sensitization, suppression of glucose absorption, modulation of gluconeogenesis, and increase of insulin secretion. The variety of bioactive components present in leaves emphasises the value of natural sources in drug development and the potential benefits of using leaf-derived medicines to treat diabetes.

In the future, the following study directions in the area of phytochemical variety in leaves with anti-diabetic potential need investigation:

- **Elucidation of Mechanisms of Action:** To fully grasp the therapeutic potential of leaf-derived phytochemicals, further clarification of the molecular pathways underlying their anti-diabetic actions is necessary. Thorough mechanistic investigations, including molecular and cellular tests, are necessary to interpret the signalling cascades and targets that facilitate the pharmaceutical impacts.
- **Identification of Novel Compounds:** Prospects for discovering novel anti-diabetic drugs seem bright when attempts to identify and describe novel bioactive chemicals from leaves continue. Employing sophisticated analytical methods like metabolomics and bioinformatics might make it easier to identify phytochemicals that were previously unidentified but have potential medical use.
- **Evaluation of Synergistic Interactions:** Investigating the phytochemicals' possible synergistic interactions might improve the medicinal effects and effectiveness of leaf extracts. Strategies for combination treatment that combine many bioactive chemicals may be able to overcome the drawbacks of single-agent therapies and provide synergistic advantages.
- **Clinical Translation and Validation:** The expeditious translation of preclinical discoveries to clinical applications is crucial in order to verify the safety and effectiveness of medicines derived from leaves in human individuals suffering from diabetes. The implementation of well planned clinical trials and real-world investigations will provide strong evidence in favour of their use in clinical practise.

Personalized Medicine Approaches: Optimizing the therapeutic response of leaf-derived anti-diabetic compounds

may require embracing personalised medicine techniques catered to unique patient profiles and genetic backgrounds. The use of precision medicine and pharmacogenomics concepts to clinical practise may reduce side effects and maximise therapeutic effectiveness.

ACKNOWLEDGEMENT: Nil

CONFLICT OF INTEREST: Nil

REFERENCES:

1. Mekala KC, Bertoni AG. Epidemiology of diabetes mellitus. In: Transplantation, bioengineering, and regeneration of the endocrine pancreas 2020 Jan 1 (pp. 49-58). Academic Press.
2. Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. *Med Sci Monit.* 2006 Jul 1;12(7):130-47.
3. Wang PC, Zhao S, Yang BY, Wang QH, Kuang HX. Anti-diabetic polysaccharides from natural sources: A review. *Carbohydrate polymers.* 2016 Sep 5;148:86-97.
4. Austin MB, Noel JP. The chalcone synthase superfamily of type III polyketide synthases. *Natural product reports.* 2003;20(1):79-110.
5. Tran N, Pham B, Le L. Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. *Biology.* 2020 Aug 28;9(9):252.
6. Wang F, Bao Y, Zhang C, Zhan L, Khan W, Siddiqua S, Ahmad S, Capanoglu E, Skalicka-Woźniak K, Zou L, Simal-Gandara J. Bioactive components and anti-diabetic properties of *Moringa oleifera* Lam. *Critical Reviews in Food Science and Nutrition.* 2022 May 9;62(14):3873-97.
7. Campbell-Tofte JI, Mølgaard P, Winther K. Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. *Botanics: targets and therapy.* 2012 Aug 22:7-19.
8. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. *The scientific world journal.* 2013 Oct 7;2013.
9. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M, Koizumi M, Ito C, Furukawa H. Quantitative study of flavonoids in leaves of Citrus plants. *Journal of agricultural and food chemistry.* 2000 Sep 18;48(9):3865-71.
10. Siddiqui AA, Siddiqui SA, Ahmad S, Siddiqui S, Ahsan I, Sahu K. Diabetes: Mechanism, pathophysiology and management-A review. *Int J Drug Dev Res.* 2013 Apr;5(2):1-23.
11. Kelly GS. Quercetin. *Alternative medicine review.* 2011 Jun 1;16(2):172-95.
12. Imran M, Salehi B, Sharifi-Rad J, Aslam Gondal T, Saeed F, Imran A, Shahbaz M, Tsouh Fokou PV, Umair Arshad M, Khan H, Guerreiro SG. Kaempferol: A key emphasis to its anticancer potential. *Molecules.* 2019 Jun 19;24(12):2277.
13. Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. *Saudi pharmaceutical journal.* 2017 Feb 1;25(2):149-64.
14. Song X, Tan L, Wang M, Ren C, Guo C, Yang B, Ren Y, Cao Z, Li Y, Pei J. Myricetin: A review of the most recent research. *Biomedicine & Pharmacotherapy.* 2021 Feb 1;134:111017.
15. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. *Mini reviews in medicinal chemistry.* 2009 Jan 1;9(1):31-59.
16. Rasouli H, Yarani R, Pociot F, Popović-Djordjević J. Anti-diabetic potential of plant alkaloids: Revisiting current

- findings and future perspectives. *Pharmacological research*. 2020 May 1;155:104723.
17. Shami AM. Isolation and identification of alkaloids extracted from local plants in Malaysia. *Ann Chromatogr Sep Tech*. 2016;2(1):1016.
 18. Dall'Asta M, Bayle M, Neasta J, Scazzina F, Bruni R, Cros G, Del Rio D, Oiry C. Protection of pancreatic β -cell function by dietary polyphenols. *Phytochemistry reviews*. 2015 Dec;14:933-59.
 19. Jiang Z, Du Q. Glucose-lowering activity of novel tetrasaccharide glyceroglycolipids from the fruits of *Cucurbita moschata*. *Bioorganic & medicinal chemistry letters*. 2011 Feb 1;21(3):1001-3.
 20. Siler SQ, Neese RA, Christiansen MP, Hellerstein MK. The inhibition of gluconeogenesis following alcohol in humans. *American Journal of Physiology-Endocrinology and Metabolism*. 1998 Nov 1;275(5):E897-907.
 21. Sheridan MA. Regulation of lipid metabolism in poikilothermic vertebrates. *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry*. 1994 Apr 1;107(4):495-508.
 22. Tillhon M, Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. *Biochemical pharmacology*. 2012 Nov 15;84(10):1260-7.
 23. Dhyani P, Quispe C, Sharma E, Bahukhandi A, Sati P, Attri DC, Szopa A, Sharifi-Rad J, Docea AO, Mardare I, Calina D. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. *Cancer cell international*. 2022 Dec;22(1):1-20.
 24. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. *Bioorganic & medicinal chemistry*. 2004 Apr 1;12(7):1585-604.
 25. Chen FE, Huang J. Reserpine: a challenge for total synthesis of natural products. *Chemical reviews*. 2005 Dec 14;105(12):4671-706.
 26. Padovan A, Keszei A, Külheim C, Foley WJ. The evolution of foliar terpene diversity in Myrtaceae. *Phytochemistry reviews*. 2014 Sep;13:695-716.
 27. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. *Diabetes technology & therapeutics*. 2004 Dec 1;6(6):850-63.
 28. Siler SQ, Neese RA, Christiansen MP, Hellerstein MK. The inhibition of gluconeogenesis following alcohol in humans. *American Journal of Physiology-Endocrinology and Metabolism*. 1998 Nov 1;275(5):E897-907.
 29. Floyd JC, Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. *The Journal of clinical investigation*. 1966 Sep 1;45(9):1487-502.
 30. Panigrahy SK, Bhatt R, Kumar A. Targeting type II diabetes with plant terpenes: The new and promising antidiabetic therapeutics. *Biologia*. 2021 Jan;76(1):241-54.
 31. Talhaoui N, Taamalli A, Gómez-Caravaca AM, Fernández-Gutiérrez A, Segura-Carretero A. Phenolic compounds in olive leaves: Analytical determination, biotic and abiotic influence, and health benefits. *Food Research International*. 2015 Nov 1;77:92-108.
 32. Søndergaard HM, Böttcher M, Marie Madsen M, Schmitz O, Hansen SB, Nielsen TT, Bøtker HE. Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease. *The Journal of Clinical Endocrinology & Metabolism*. 2006 Dec 1;91(12):4854-61.
 33. bu Kang B, huang Chiang B. A novel phenolic formulation for treating hepatic and peripheral insulin resistance by regulating GLUT4-mediated glucose uptake. *Journal of Traditional and Complementary Medicine*. 2022 Mar 1;12(2):195-205.
 34. Frémont L. Biological effects of resveratrol. *Life sciences*. 2000 Jan 14;66(8):663-73.
 35. Singh P, Arif Y, Bajguz A, Hayat S. The role of quercetin in plants. *Plant Physiology and Biochemistry*. 2021 Sep 1;166:10-9.
 36. Stuart EC, Scandlyn MJ, Rosengren RJ. Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. *Life sciences*. 2006 Nov 17;79(25):2329-36.
 37. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. *European journal of cancer*. 2005 Sep 1;41(13):1955-68.
 38. Lalia AZ, Lanza IR. Insulin-sensitizing effects of omega-3 fatty acids: lost in translation?. *Nutrients*. 2016 Jun 1;8(6):329.
 39. Sayem AS, Arya A, Karimian H, Krishnasamy N, Ashok Hasamnis A, Hossain CF. Action of phytochemicals on insulin signaling pathways accelerating glucose transporter (GLUT4) protein translocation. *Molecules*. 2018 Jan 28;23(2):258.
 40. Ryder JW, Chibalin AV, Zierath JR. Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. *Acta Physiologica Scandinavica*. 2001 Mar;171(3):249-57.
 41. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. *Acta physiologica*. 2006 Jan;186(1):5-16.
 42. Gromova LV, Fetisov SO, Gruzdkov AA. Mechanisms of glucose absorption in the small intestine in health and metabolic diseases and their role in appetite regulation. *Nutrients*. 2021 Jul 20;13(7):2474.
 43. Castañeda AM, Dutra-Rufato A, Juarez MJ, Grosembacher L, Gonzalez-Torres H, Musso CG. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications. *International Urology and Nephrology*. 2021 Feb;53:291-9.
 44. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. *Annual review of nutrition*. 1999 Jul;19(1):379-406.
 45. Zhang X, Yang S, Chen J, Su Z. Unraveling the regulation of hepatic gluconeogenesis. *Frontiers in endocrinology*. 2019 Jan 24;9:802.
 46. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. *American Journal of Physiology-Endocrinology And Metabolism*. 1999 Jun 1;276(6):E1055-66.
 47. Newsholme P, Keane KN, Carlessi R, Cruzat V. Oxidative stress pathways in pancreatic β -cells and insulin-sensitive cells and tissues: importance to cell metabolism, function, and dysfunction. *American Journal of Physiology-Cell Physiology*. 2019 Sep 1;317(3):C420-33.
 48. Ferlemi AV, Lamari FN. Berry leaves: An alternative source of bioactive natural products of nutritional and medicinal value. *Antioxidants*. 2016 Jun 1;5(2):17.
 49. Altemimi A, Lakhssassi N, Baharlouei A, Watson DG, Lightfoot DA. Phytochemicals: Extraction, isolation, and identification of bioactive compounds from plant extracts. *Plants*. 2017 Sep 22;6(4):42.

50. Salehi B, Ata A, V. Anil Kumar N, Sharopov F, Ramírez-Alarcón K, Ruiz-Ortega A, Abdulmajid Ayatollahi S, Valere Tsouh Fokou P, Kobarfard F, Amiruddin Zakaria Z, Iriti M. Antidiabetic potential of medicinal plants and their active components. *Biomolecules*. 2019 Sep 30;9(10):551.
51. Ghorbani A. Best herbs for managing diabetes: a review of clinical studies. *Brazilian Journal of Pharmaceutical Sciences*. 2013;49:413-22.
52. Priyandoko D, Ishii T, Kaul SC, Wadhwa R. Ashwagandha leaf derived withanone protects normal human cells against the toxicity of methoxyacetic acid, a major industrial metabolite. *Plos one*. 2011 May 4;6(5):e19552.
53. Parida IS, Takasu S, Nakagawa K. A comprehensive review on the production, pharmacokinetics and health benefits of mulberry leaf iminosugars: main focus on 1-deoxynojirimycin, d-fagomine, and 2-O- α -d-galactopyranosyl-DNJ. *Critical Reviews in Food Science and Nutrition*. 2023 Jul 26;63(19):3468-96.
54. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challenges for clinical translation. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 2015 Jun 1;1852(6):1178-85.
55. Petrova E. Innovation in the pharmaceutical industry: The process of drug discovery and development. In *Innovation and Marketing in the Pharmaceutical Industry: Emerging Practices, Research, and Policies 2013* Oct 26 (pp. 19-81). New York, NY: Springer New York.

How to Cite this article:

Gupta R, Kumar GP, Singh G, Malik J, Singh SP, Kumar S. Exploring bioactive constituents: a review on the phytochemical diversity of leaves with anti-diabetic activity. *International Journal of Pharmaceutical Science and Medicine* 2024; 2(1): 7-14. DOI: 10.70199/IJPSM.2.1.7-14